131 related articles for article (PubMed ID: 28808840)
1. Comparison of health state values derived from patients and individuals from the general population.
Gandhi M; Tan RS; Ng R; Choo SP; Chia WK; Toh CK; Lam C; Lee PT; Latt NKZ; Rand-Hendriksen K; Cheung YB; Luo N
Qual Life Res; 2017 Dec; 26(12):3353-3363. PubMed ID: 28808840
[TBL] [Abstract][Full Text] [Related]
2. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set.
Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM
Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730
[TBL] [Abstract][Full Text] [Related]
3. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets.
Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A
Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577
[TBL] [Abstract][Full Text] [Related]
4. An EQ-5D-5L value set based on Uruguayan population preferences.
Augustovski F; Rey-Ares L; Irazola V; Garay OU; Gianneo O; Fernández G; Morales M; Gibbons L; Ramos-Goñi JM
Qual Life Res; 2016 Feb; 25(2):323-333. PubMed ID: 26242249
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life of patients with HIV/AIDS at a tertiary care teaching hospital in Ethiopia.
Belay YB; Ali EE; Sander B; Gebretekle GB
Health Qual Life Outcomes; 2021 Jan; 19(1):24. PubMed ID: 33468153
[TBL] [Abstract][Full Text] [Related]
6. The Utility of 5 Hypothetical Health States in Heart Failure Using Time Trade-Off (TTO) and EQ-5D-5L in Korea.
Hong SH; Lee JY; Park SK; Nam JH; Song HJ; Park SY; Lee EK
Clin Drug Investig; 2018 Aug; 38(8):727-736. PubMed ID: 29804184
[TBL] [Abstract][Full Text] [Related]
7. Valuing Health Using Time Trade-Off and Discrete Choice Experiment Methods: Does Dimension Order Impact on Health State Values?
Mulhern B; Shah K; Janssen MF; Longworth L; Ibbotson R
Value Health; 2016; 19(2):210-7. PubMed ID: 27021755
[TBL] [Abstract][Full Text] [Related]
8. Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States.
Burström K; Teni FS; Gerdtham UG; Leidl R; Helgesson G; Rolfson O; Henriksson M
Pharmacoeconomics; 2020 Aug; 38(8):839-856. PubMed ID: 32307663
[TBL] [Abstract][Full Text] [Related]
9. Questioning the differences between general public vs. patient based preferences towards EQ-5D-5L defined hypothetical health states.
Ogorevc M; Murovec N; Fernandez NB; Rupel VP
Health Policy; 2019 Feb; 123(2):166-172. PubMed ID: 28410808
[TBL] [Abstract][Full Text] [Related]
10. The EQ-5D-5L Valuation study in Thailand.
Pattanaphesaj J; Thavorncharoensap M; Ramos-Goñi JM; Tongsiri S; Ingsrisawang L; Teerawattananon Y
Expert Rev Pharmacoecon Outcomes Res; 2018 Oct; 18(5):551-558. PubMed ID: 29958008
[TBL] [Abstract][Full Text] [Related]
11. The EQ-5D-5L valuation study in Korea.
Kim SH; Ahn J; Ock M; Shin S; Park J; Luo N; Jo MW
Qual Life Res; 2016 Jul; 25(7):1845-52. PubMed ID: 26961008
[TBL] [Abstract][Full Text] [Related]
12. Dutch Tariff for the Five-Level Version of EQ-5D.
M Versteegh M; M Vermeulen K; M A A Evers S; de Wit GA; Prenger R; A Stolk E
Value Health; 2016 Jun; 19(4):343-52. PubMed ID: 27325326
[TBL] [Abstract][Full Text] [Related]
13. Comparison of general population, patient, and carer utility values for dementia health states.
Rowen D; Mulhern B; Banerjee S; Tait R; Watchurst C; Smith SC; Young TA; Knapp M; Brazier JE
Med Decis Making; 2015 Jan; 35(1):68-80. PubMed ID: 25385749
[TBL] [Abstract][Full Text] [Related]
14. A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada.
Xie F; Pullenayegum E; Gaebel K; Bansback N; Bryan S; Ohinmaa A; Poissant L; Johnson JA;
Med Care; 2016 Jan; 54(1):98-105. PubMed ID: 26492214
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life measured using the EQ-5D-5L: South Australian population norms.
McCaffrey N; Kaambwa B; Currow DC; Ratcliffe J
Health Qual Life Outcomes; 2016 Sep; 14(1):133. PubMed ID: 27644755
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan.
Shiroiwa T; Ikeda S; Noto S; Igarashi A; Fukuda T; Saito S; Shimozuma K
Value Health; 2016; 19(5):648-54. PubMed ID: 27565282
[TBL] [Abstract][Full Text] [Related]
17. Comparison of EQ-5D-5L, VAS, and SF-6D in Thai Patients on Peritoneal Dialysis.
Thaweethamcharoen T; Noparatayaporn P; Sritippayawan S; Aiyasanon N
Value Health Reg Issues; 2019 May; 18():59-64. PubMed ID: 30502661
[TBL] [Abstract][Full Text] [Related]
18. Valuation of Quality Weights for EuroQol 5-Dimensional Health States With the Time Trade-Off Method in the Capital of Iran.
Goudarzi R; Sari AA; Zeraati H; Rashidian A; Mohammad K; Amini S
Value Health Reg Issues; 2019 May; 18():170-175. PubMed ID: 31096140
[TBL] [Abstract][Full Text] [Related]
19. Comparing the EQ-5D-5L crosswalks and value sets for England, the Netherlands and Spain: Exploring their impact on cost-utility results.
Ben Â; Finch AP; van Dongen JM; de Wit M; van Dijk SEM; Snoek FJ; Adriaanse MC; van Tulder MW; Bosmans JE
Health Econ; 2020 May; 29(5):640-651. PubMed ID: 32059078
[TBL] [Abstract][Full Text] [Related]
20. Elicitation of Norwegian EQ-5D-5L values for hypothetical and experience-based health states based on the EuroQol Valuation Technology (EQ-VT) protocol.
Hansen TM; Helland Y; Augestad LA; Rand K; Stavem K; Garratt A
BMJ Open; 2020 Jun; 10(6):e034683. PubMed ID: 32532768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
